Alfredo Juárez-Saldivar

Mr. Alfredo Juárez-Saldivar

Instituto Politécnico Nacional
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
MSMichael Schroeder
Michael Schroeder
SSSebastian Salentin
Sebastian Salentin
VHV. Joachim Haupt
V. Joachim Haupt
ESEmma Saavedra
Emma Saavedra
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects nearly eight million people worldwide. There are currently only limited treatment options, which cause several side effects and have drug resistance. Thus, there is a great need for a novel, improved Chagas treatment. Bifunctional enzyme dihydrofolate reductase-thymidylate synthase (DHFR-TS) has emerged as a promising pharmacological target. Moreover, some human dihydrofolate reductase (HsDHFR) inhibitors such as trimetrexate also inhibit T. cruzi DHFR-TS (TcDHFR-TS). These compounds serve as a starting point and a reference in a screening campaign to search for new TcDHFR-TS inhibitors. In this paper, a novel virtual screening approach was developed that combines classical docking with protein-ligand interaction profiling to identify drug repositioning opportunities against T. cruzi infection. In this approach, some food and drug administration (FDA)-approved drugs that were predicted to bind with high affinity to TcDHFR-TS and whose predicted molecular interactions are conserved among known inhibitors were selected. Overall, ten putative TcDHFR-TS inhibitors were identified. These exhibited a similar interaction profile and a higher computed binding affinity, compared to trimetrexate. Nilotinib, glipizide, glyburide and gliquidone were tested on T. cruzi epimastigotes and showed growth inhibitory activity in the micromolar range. Therefore, these compounds could lead to the development of new treatment options for Chagas disease.

Verified
Journal Article
Open access
PDF file
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
EBELIZABETH BARBOSA
ELIZABETH BARBOSA
ELEdgar E. Lara-Ramírez
Edgar E. Lara-Ramírez
APALMA PAZ
ALMA PAZ
Verónica Martínez-VázquezVerónica Martínez-Vázquez
Verónica Martínez-Vázquez
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Infectious diseases caused by intestinal protozoan, such as Entamoeba histolytica (E. histolytica) and Giardia lamblia (G. lamblia) are a worldwide public health issue. They affect more than 70 million people every year. They colonize intestines causing primarily diarrhea; nevertheless, these infections can lead to more serious complications. The treatment of choice, metronidazole, is in doubt due to adverse effects and resistance. Therefore, there is a need for new compounds against these parasites. In this work, a structure-based virtual screening of FDA-approved drugs was performed to identify compounds with antiprotozoal activity. The glycolytic enzyme triosephosphate isomerase, present in both E. histolytica and G. lamblia, was used as the drug target. The compounds with the best average docking score on both structures were selected for the in vitro evaluation. Three compounds, chlorhexidine, tolcapone, and imatinib, were capable of inhibit growth on G. lamblia trophozoites (0.05–4.935 μg/mL), while folic acid showed activity against E. histolytica (0.186 μg/mL) and G. lamblia (5.342 μg/mL).

Verified
Journal Article
Open access
PDF file
LVLenci K. Vázquez-Jiménez
Lenci K. Vázquez-Jiménez
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
RGRogelio Gómez-Escobedo
Rogelio Gómez-Escobedo
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
DADomingo Mendez Alvarez
Domingo Mendez Alvarez
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Trypanosoma cruzi (T. cruzi) is a parasite that affects humans and other mammals. T. cruzi depends on glycolysis as a source of adenosine triphosphate (ATP) supply, and triosephosphate isomerase (TIM) plays a key role in this metabolic pathway. This enzyme is an attractive target for the design of new trypanocidal drugs. In this study, a ligand-based virtual screening (LBVS) from the ZINC15 database using benzimidazole as a scaffold was accomplished. Later, a molecular docking on the interface of T. cruzi TIM (TcTIM) was performed and the compounds were grouped by interaction profiles. Subsequently, a selection of compounds was made based on cost and availability for in vitro evaluation against blood trypomastigotes. Finally, the compounds were analyzed by molecular dynamics simulation, and physicochemical and pharmacokinetic properties were determined using SwissADME software. A total of 1604 molecules were obtained as potential TcTIM inhibitors. BP2 and BP5 showed trypanocidal activity with half-maximal lytic concentration (LC50) values of 155.86 and 226.30 µM, respectively. Molecular docking and molecular dynamics simulation analyzes showed a favorable docking score of BP5 compound on TcTIM. Additionally, BP5 showed a low docking score (−5.9 Kcal/mol) on human TIM compared to the control ligand (−7.2 Kcal/mol). Both compounds BP2 and BP5 showed good physicochemical and pharmacokinetic properties as new anti-T. cruzi agents.

1 April 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
LVLenci K. Vázquez-Jiménez
Lenci K. Vázquez-Jiménez
AMAntonio Moreno-Herrera
Antonio Moreno-Herrera
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
AGAlonzo Gonzalez-Gonzalez
Alonzo Gonzalez-Gonzalez
EOEyra Ortiz-Pérez
Eyra Ortiz-Pérez
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Background: Parasitic diseases caused by protozoa, such as Chagas disease, leishmaniasis, malaria, African trypanosomiasis, amoebiasis, trichomoniasis, and giardiasis, are considered serious public health problems in developing countries. Drug resistance among parasites justifies the search for new therapeutic drugs, and the identification of new targets becomes a valuable approach. In this scenario, the glycolysis pathway, which converts glucose into pyruvate, plays an important role in the protozoa energy supply, and it is therefore considered a promising target. In this pathway, triose phosphate isomerase (TIM) plays an essential role in efficient energy production. Furthermore, protozoa TIM shows structural differences with human enzyme counterparts, suggesting the possibility of obtaining selective inhibitors. Therefore, TIM is considered a valid approach to develop new antiprotozoal agents, inhibiting the glycolysis in the parasite. Objective: In this review, we discuss the drug design strategies, structure-activity relationship, and binding modes of outstanding TIM inhibitors against Trypanosoma cruzi, Trypanosoma brucei, Plasmodium falciparum, Giardia lamblia, Leishmania mexicana, Trichomonas vaginalis, and Entamoeba histolytica. Results: TIM inhibitors have mainly shown aromatic systems and symmetrical structure, where the size and type of heteroatom are important for enzyme inhibition. This inhibition is mainly based on the interaction with i) the interfacial region of TIM inducing changes on the quaternary and tertiary structure or ii) with the TIM catalytic region, the main pathways that disable the catalytic activity of the enzyme. Conclusion: Benzothiazole, benzoxazole, benzimidazole, and sulfhydryl derivatives stand out as TIM inhibitors. In silico and in vitro studies have demonstrated that the inhibitors bind mainly at the TIM dimer interface. In this review, the development of new TIM inhibitors as antiprotozoal drugs is demonstrated as an important pharmaceutical strategy that may lead to new therapies for these ancient parasitic diseases.

29 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Luis Donaldo Gonzalez MoralesLuis Donaldo Gonzalez Morales
Luis Donaldo Gonzalez Morales
ARAdriana Moreno Rodriguez Adriana Moreno Rodríguez
Adriana Moreno Rodriguez Adriana Moreno Rodríguez
LVLenci K. Vázquez-Jiménez
Lenci K. Vázquez-Jiménez
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Cutaneous leishmaniasis (CL) is a public health problem affecting more than 98 countries worldwide. No vaccine is available to prevent the disease, and available medical treatments cause serious side effects. Additionally, treatment failure and parasite resistance have made the development of new drugs against CL necessary. In this work, a virtual screening of natural products from the BIOFACQUIM and Selleckchem databases was performed using the method of molecular docking at the triosephosphate isomerase (TIM) enzyme interface of Leishmania mexicana (L. mexicana). Finally, the in vitro leishmanicidal activity of selected compounds against two strains of L. mexicana, their cytotoxicity, and selectivity index were determined. The top ten compounds were obtained based on the docking results. Four were selected for further in silico analysis. The ADME-Tox analysis of the selected compounds predicted favorable physicochemical and toxicological properties. Among these four compounds, S-8 (IC50 = 55 µM) demonstrated a two-fold higher activity against the promastigote of both L. mexicana strains than the reference drug glucantime (IC50 = 133 µM). This finding encourages the screening of natural products as new anti-leishmania agents.

1 December 2024 in Bioactive Materials
Verified
Journal Article
Open access
SCSilvia Cometta
Silvia Cometta
BDBogdan Donose
Bogdan Donose
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
ARAkhilandeshwari Ravichandran
Akhilandeshwari Ravichandran
YXYanan Xu
Yanan Xu
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
Biofilm-related biomaterial infections are notoriously challenging to treat and can lead to chronic infection and persisting inflammation. To date, a large body of research can be reviewed for coatings which potentially prevent bacterial infection while promoting implant integration. Yet only a very small number has been translated from bench to bedside. This study provides an in-depth analysis of the stability, antibacterial mechanism, and biocompatibility of medical grade polycaprolactone (mPCL), coated with human serum albumin (HSA), the most abundant protein in blood plasma, and tannic acid (TA), a natural polyphenol with antibacterial properties. Molecular docking studies demonstrated that HSA and TA interact mainly through hydrogen-bonding, ionic and hydrophobic interactions, leading to smooth and regular assemblies. In vitro bacteria adhesion testing showed that coated scaffolds maintained their antimicrobial properties over 3 days by significantly reducing S. aureus colonization and biofilm formation. Notably, amplitude modulation-frequency modulation (AMFM) based viscoelasticity mapping and transmission electron microscopy (TEM) data suggested that HSA/TA-coatings cause morphological and mechanical changes on the outer cell membrane of S. aureus leading to membrane disruption and cell death while proving non-toxic to human primary cells. These results support this antibiotic-free approach as an effective and biocompatible strategy to prevent biofilm-related biomaterial infections.